Academy of Sleep Wake Science, #32 St.no-9 Guru Nanak Nagar, near Gurbax Colony, Patiala, Punjab, India 147003.
Sleep Med Clin. 2022 Mar;17(1):87-98. doi: 10.1016/j.jsmc.2021.10.007.
Sleep-disordered breathing (SDB) is highly prevalent in patients with heart failure (HF). Untreated obstructive sleep apnea (OSA) and central sleep apnea (CSA) in patients with HF are associated with worse outcomes. Detailed sleep history along with polysomnography (PSG) should be conducted if SDB is suspected in patients with HF. First line of treatment is the optimization of medical therapy for HF and if symptoms persist despite optimization of the treatment, positive airway pressure (PAP) therapy will be started to treat SDB. At present, there is limited evidence to prescribe any drugs for treating CSA in patients with HF. There is limited evidence for the efficacy of continuous positive airway pressure (CPAP) or adaptive servo-ventilation (ASV) in improving mortality in patients with heart failure with reduced ejection fraction (HFrEF). There is a need to perform well-designed studies to identify different phenotypes of CSA/OSA in patients with HF and to determine which phenotype responds to which therapy. Results of ongoing trials, ADVENT-HF, and LOFT-HF are eagerly awaited to shed more light on the management of CSA in patients with HF. Until then the management of SDB in patients with HF is limited due to the lack of evidence and guidance for treating SDB in patients with HF.
睡眠呼吸障碍(SDB)在心力衰竭(HF)患者中非常普遍。未经治疗的阻塞性睡眠呼吸暂停(OSA)和心力衰竭患者的中枢性睡眠呼吸暂停(CSA)与更差的结局相关。如果怀疑 HF 患者存在 SDB,则应进行详细的睡眠史记录和多导睡眠图(PSG)检查。一线治疗是优化 HF 的药物治疗,如果尽管优化了治疗,但症状仍然持续存在,则将开始使用正压气道通气(PAP)治疗来治疗 SDB。目前,对于 HF 患者 CSA 的治疗,仅有有限的证据推荐使用任何药物。CPAP 或适应性伺服通气(ASV)在改善射血分数降低的心力衰竭(HFrEF)患者死亡率方面的疗效证据有限。需要进行精心设计的研究,以确定 HF 患者中 CSA/OSA 的不同表型,并确定哪种表型对哪种治疗有反应。正在进行的 ADVENT-HF 和 LOFT-HF 试验的结果,有望进一步阐明 HF 患者 CSA 的管理。在此之前,由于缺乏 HF 患者 SDB 治疗的证据和指南,HF 患者的 SDB 管理受到限制。